With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.943757-71-9,(R)-2-(Diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine,as a common compound, the synthetic route is as follows.
943757-71-9, To a solution of trans-cinnamaldehyde (134.2 g, 1.015 mol) in methanol (2 L), (2R)-2-[diphenyl[(trimethylsilyl)oxy]methyl]pyrrolidine (16.5 g, 50.6 mmol), nitroethanol (138.8 g, 1.524 mol), and benzoic acid (12.4 g, 101.5 mmol) were added, and the mixture was stirred at room temperature for 3 days under nitrogen atmosphere. Sodium bicarbonate (424.2 g, 5.05 mol) was added thereto, and the mixture was further stirred for 12 hours. The reaction solution was concentrated under reduced pressure, distilled water was added thereto, followed by extraction with ethyl acetate. The obtained organic layer was dried over sodium sulfate and filtered, and then the filtrate was concentrated under reduced pressure. After the residue was dissolved in a mixed solvent of ethyl acetate and hexane (1:1) under heating at 80C, the reaction solution was stirred and gradually cooled to room temperature. After 3 hours, the precipitated solid was filtered out to obtain (4R,5R)-4-phenyl-5-nitrotetrahydro-2H-pyran-2-ol (128.68 g, 0.576 mol, >99%ee).
943757-71-9 (R)-2-(Diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine 16218310, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Patent; Sumitomo Dainippon Pharma Co., Ltd.; IKUMA Yohei; FUKUDA Nobuhisa; IWATA Masato; KIMURA Hidenori; SUZUKI Kuniko; EP2876105; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI